The Experience Exchange
The Experience Exchange (formally the exhibit hall) is an open-format, interactive meeting place designed to foster the exchange of groundbreaking scientific information through non-ce educational programming and networking opportunities.
This dynamic space allows attendees to easily navigate the space and receive additional one-on-one time with speakers, exhibitors, and other pain science professionals.
What to Expect
Learning
Extended Poster Viewing allows all posters in one place at one time. View the list of accepted posters to see what will be presented.
The Learning Lounge, an innovative, interactive theater were both industry and association driven content can be delivered. The Learning Lounge is the 'hub' of the Experience Exchange. The Learning Lounge will host Town Hall Talks and Session Sound Bytes.
Town Hall Talks will showcase products, services, and programs, relevant to your profession. Topics can range from risk evaluation and mitigation strategies (REMS), compliance, patient safety, diversion, and research. All Town Hall Talks are SOLD OUT!
Town Hall Talks will be presented at the following times:
Wednesday, May 13
4:45-5:45 pm
Pain Matters: Patient and Provider Perspectives on Pain Management
This program features a screening of "Pain Matters," a Discovery Channel documentary, followed by a panel discussion with individuals from the film exploring patient and provider perspectives on pain management.
This is a non-CME event sponsored by Teva Pharmaceuticals.
Thursday, May 14
9:45-10:45 am
Putting Patients First: Developing Abuse-Deterrent Opioids
Joseph P. Valenza, MD, Director of Pain Management, Kessler Institute for Rehabilitation
This program examines the FDA draft guidance for the pharmaceutical industry on developing formulations of opioid drug products with potentially abuse‐deterrent properties.
Sponsored by Teva
12:45-1:15 pm
Opioid-Induced Constipation: The Science, the Struggle, and an Orally Administered Treatment Option
Gerald M. Sacks, MD
A presentation on one of the most common side effects of opioids, opioid-induced constipation (OIC), its impact on the patient, and an orally administered treatment option for adult patients with chronic non-cancer pain.
Sponsored by AstraZeneca
1:30-2 pm
Kappa Opioid Receptor Agonists (KORAs) - Moving Beyond Mu
Lynn Webster, MD; Joseph Stauffer, DO MBA
One of the key challenges facing Clinicians today is how to manage the dueling crises of pain and addiction. Mu Opioid agents are the standard of care, but even Abuse Deterrent Formations are not solving the abuse and addiction crisis. This session will chart the scientific and clinical progress of a new class of analgesics, the Kappa Opioid Receptor Agonists. (KORAs). By working in the peripheral system and not entering the CNS, these agents may provide the analgesia that patients need, whilst avoiding the troublesome A/Es that are typical of Mu Opioid therapy.
Sponsored by Cara Therapeutics.
4-5 pm
An Extended-Release Oral Hydrocodone Bitartrate Therapy
Dr. Gerald Aronoff
Join your colleagues for this informative showcase, where Dr. Gerald Aronoff, will discuss An extended-release oral hydrocodone bitartrate therapy. Full Prescribing Information, including Boxed Warning, will be distributed and discussed at the presentation
Sponsored by Purdue Pharma L.P.
Session Sound Bytes (TED-style talks) featuring recaps of the most popular and relevant sessions on Friday, May 15. The Session Sound Bytes provides an opportunity to interact with the speakers and engage in dialogue on clinical and basic science topics.
The following individuals will be featured:
Publishing Your Research Findings: Strategies for Success
Dissemination of research findings is a central goal of successful researchers. In order for their research findings to reach the largest audiences, and have the most influence on the field, researchers often seek to publish their findings in journals with high impact factors. In this talk, Dr. Jensen, the Editor-in-Chief of The Journal of Pain, and author of over 350 articles in peer-reviewed journals, will describe the most common problems seen in articles submitted for publication in the journal, and make specific recommendations for how to avoid those problems. He will also be available to discuss questions that the session participants may have regarding how to go about publishing scientific papers.
9:10–9:30 am: Hants Williams, BSN
Behavioral Health Needs and Hospital Utilization in Persons with Sickle Cell Disease
In this short sound byte, hospital utilization and unmet psychological and social needs will be examined in the context of Sickle Cell Disease. Talking points will include psychological symptoms of Sickle Cell Disease that are often undertreated, social barriers, and how hospital utilization may be impacted by these and other psychosocial factors.
9:35–9:55 am: Linda Watkins, PhD
XT-150 (non-viral Interleutkin-10 gene therapy): Application for Investigational New Drug status supports efficacy of this anti-inflammatory cytokine strategy for neuropathic pain and osteoarthritis
Over the past 25 years, evidence has accrued from many labs across the world that activation of CNS glia and peripheral immune cells are importantly involved in the creation and maintenance of pathological pain states. These cells amplify pain via the release of neuroexcitatory, pain-enhancing substances. Key amongst these is a family of pro-inflammatory cytokines, intereukin-1beta (IL-1®), tumor necrosis factor-alpha (TNF), and IL-6. Through 9 generations of development over the past 15 years, a clinically appropriate therapeutic has been optimized which utilizes non-viral gene therapy to drive the production of a potent, endogenous anti-inflammatory cytokine, IL-10. IL-10 is an ideal therapeutic as it suppresses the production and function of the entire family of pro-inflammatory cytokines and their downstream mediators. Localized delivery to intrathecal as well as intra-articular spaces is efficacious in producing several months of pain resolution in response to a single injection. Notably, both openlabel and blinded studies of pet (companion) dogs with long-standing intractable pain support its enduring efficacy for relieving both neuropathic and osteoarthritic pain following intrathecal or intra-articular delivery, respectively. Based on preclinical efficacy in mice, rats and companion dogs, successful scale-up manufacturing and positive outcomes in FDA dictated toxicology studies of up to 6 months duration, application for Investigational New Drug status for XT101 will be sought.
10–10:20 am: Mark Ware, MD MRCP (UK) MSc
A Strategic Approach to Cannabis Research
In this session I hope to build a framework for clinical cannabis research that reflects the reality that cannabis is a drug that many patients already use as a self management approach to their pain. This unique situation presents opportunities for research that includes case reports and series, observational epidemiological research, and where circumstances allow, small scale clinical trials, as well as prospective studies of safety concerns. Such work may also serve to generate hypotheses for future research. Concerns around standardization of products and laboratories and methods will be reviewed and discussed.
Claudia Campbell, PhD, will serve as moderator.
Networking
Connection Centrals networking areas will be set-up in the Experience Exchange to meet and interact with other attendees. These desginated areas great for those one-on-one meetings or for a casual discussion.
Navigating
A new design layout to enhance collaboration.
Explore the Floor is an unique way for attendees to navigate the Experience Exchange. This new interactive experience allows attendees and exhibitors to discuss products and services that will benefit the pain science profession. Attendees will receive an explorer card to be stamped at select booths. Once the card is filled, enter the card into this year's prize drawing.